Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Chemotherapy For Pancreatic Cancer Strengthened By Vitamin A

XTALKS VITALS NEWS

Chemotherapy

Gemcitabine chemotherapy was paired with vitamin A, and the researchers noted both a reduction in cancer cell proliferation and invasion of surrounding tissue.

Share this!

May 26, 2016 | by Sarah Massey, M.Sc.

By combining chemotherapy and vitamin A, researchers have successfully reduced pancreatic cancer cell proliferation Tweet: Combining #chemotherapy and vitamin A reduced #pancreaticcancer proliferation http://ctt.ec/8ofYw+. Pancreatic cancer is one of the deadliest forms of the disease, with a survival rate of just 3 percent.

Traditional cancer treatment strategies – including chemotherapy and radiotherapy – are relatively ineffective against pancreatic cancer. While surgery has a higher success rate at removing the tumor tissue, the cancer has most often already metastasized by the time a diagnosis is made.

To develop a new approach to pancreatic cancer treatment, researchers at QMUL's Barts Cancer Institute focused on a new drug target: stromal cells. Up to 80 percent of pancreatic cancer tissue is made up of stromal cells, which surround and communicate with the cancer cells. These relatively-normal cells have a major impact on the progression of the pancreatic tumor, making them a key target for new cancer therapies.

Using both cell cultures and mice models, the researchers tested a combined therapy targeting both the cancerous tissue, and the surrounding stromal cells. Gemcitabine chemotherapy was paired with vitamin A, and the researchers noted both a reduction in cancer cell proliferation and invasion of surrounding tissue.

“This is the first time that we have combined vitamin A with chemotherapy for pancreatic cancer,” said Professor Hemant Kocher from QMUL's Barts Cancer Institute. “The results are so promising that we're now taking this into a clinical trial.”



By targeting both cell types, the researchers believe that multiple cell signaling pathways used by cancer cells to spread, could be interrupted. If the cancer cells are unable to communicate with the surrounding stromal cells, the tumor is unable to grow as aggressively as it would in the absence of treatment.

“Pancreatic cancer is extremely hard to treat by chemotherapy, so this finding is important because vitamin A targets the non-cancerous tissue and makes the existing chemotherapy more effective, killing the cancer cells and shrinking tumors,” said Kocher. “This could potentially be applicable to other cancers because if we try to understand the cancer as a whole, including its surrounding tissue, we may be able to develop new and better treatments.”

As a result of the preclinical studies, the researchers have now launched a clinical trial, STARPAC, to test the effectiveness of the combination therapy in patients. The trial – led by Barts Cancer Institute's Centre for Experimental Cancer Medicine – is currently recruiting participants.

“The majority of experimental work was done as part of my PhD project, and I am excited that our hard work in the laboratory is now being tested in the form of a clinical trial,” said QMUL PhD student Elisabete Carapuça. “We hope that it will benefit patients facing this awful disease.”


Keywords: Pancreatic Cancer, Clinical Trial, Combination Therapy


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Gilead’s Newest Hepatitis C Drug Gets FDA Approval

July 21, 2017 - Dominant player in the chronic hepatitis C virus (HCV) market Gilead has received US Food and Drug Administration (FDA) approval for its newest treatment, Vosevi.

Featured In: Pharmaceutical News


Detecting Alzheimer’s Biomarkers in the Blood Could Improve Early Diagnosis

July 20, 2017 - In an effort to improve rates of early diagnosis and intervention, researchers at Washington University in St. Louis have developed a blood test that can detect some of the hallmarks of Alzheimer’s disease.

Featured In: Biotech News


Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.